Skip to main content
. Author manuscript; available in PMC: 2022 Dec 1.
Published in final edited form as: Am J Gastroenterol. 2021 Dec 1;116(12):2374–2384. doi: 10.14309/ajg.0000000000001501

Table 3.

Frequency of presentation of patients with pooled immune-mediated diseases.

Variables Autoimmune gastritis (n=60) Controls (n=30) Odds ratioa 95%CI p value
I. Pooled immune-mediated diseases n (%)b
 Including immune thyroid diseasec 42 (70.0) 8 (26.7) 11.67 3.49–39.05 <0.001
 Excluding immune thyroid disease 23 (38.3) 4 (13.3) 5.55 1.53–20.17 0.009
II. Pooled mucocutaneous immune-mediated diseases n (%)d
 Including immune thyroid disease 40 (66.7) 7 (23.3) 12.02 3.51–41.13 <0.001
 Excluding immune thyroid disease 18 (30.0) 3 (10.0) 4.75 1.18–19.16 0.029
III. Investigational hypotheses n (%)e 15 (25.0) 2 (6.7) 6.82 1.27–36.72 0.025
a

Odds ratio adjusted for sex, age, H. pylori, tobacco use and alcohol consumption. Significance p<0.05.

b

“Pooled immune-mediated diseases”: vitiligo, alopecia areata, lichen planus, Sjögren’s syndrome, urticaria, lupus, dermatomyositis, scleroderma, morphea, lichen sclerosus, vasculitis, panniculitis, psoriasis, hidradenitis suppurativa, immune arthritis, type 1 diabetes mellitus, adrenal insufficiency, coeliac disease and polymyalgia rheumatica.

c

Immune thyroid disease: Hashimoto’s thyroiditis and hyperthyroidism.

d

“Pooled mucocutaneous immune-mediated diseases”: vitiligo, alopecia areata, lichen planus, Sjögren’s syndrome, urticaria, lupus, dermatomyositis, scleroderma, morphea, lichen sclerosus, vasculitis, panniculitis, psoriasis and hydradenitis suppurativa.

e

“Investigation hypothesis”: vitiligo, alopecia areata, Sjögren’s syndrome and coeliac disease.